Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 176.09
TARO's Cash to Debt is ranked higher than
66% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. TARO: 176.09 )
Ranked among companies with meaningful Cash to Debt only.
TARO' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.50 Max: N/A
Current: 176.09
Equity to Asset 0.85
TARO's Equity to Asset is ranked higher than
86% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TARO: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
TARO' s 10-Year Equity to Asset Range
Min: 0.23  Med: 0.54 Max: 0.85
Current: 0.85
0.23
0.85
Interest Coverage 568.57
TARO's Interest Coverage is ranked lower than
53% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. TARO: 568.57 )
Ranked among companies with meaningful Interest Coverage only.
TARO' s 10-Year Interest Coverage Range
Min: 1.47  Med: 5.62 Max: 568.57
Current: 568.57
1.47
568.57
F-Score: 7
Z-Score: 15.74
M-Score: -1.76
WACC vs ROIC
7.28%
82.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 64.08
TARO's Operating margin (%) is ranked higher than
99% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. TARO: 64.08 )
Ranked among companies with meaningful Operating margin (%) only.
TARO' s 10-Year Operating margin (%) Range
Min: -27.89  Med: 16.57 Max: 61.14
Current: 64.08
-27.89
61.14
Net-margin (%) 57.15
TARO's Net-margin (%) is ranked higher than
98% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. TARO: 57.15 )
Ranked among companies with meaningful Net-margin (%) only.
TARO' s 10-Year Net-margin (%) Range
Min: -32.77  Med: 10.20 Max: 56.12
Current: 57.15
-32.77
56.12
ROE (%) 41.48
TARO's ROE (%) is ranked higher than
92% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. TARO: 41.48 )
Ranked among companies with meaningful ROE (%) only.
TARO' s 10-Year ROE (%) Range
Min: -92.98  Med: 19.23 Max: 49.88
Current: 41.48
-92.98
49.88
ROA (%) 34.20
TARO's ROA (%) is ranked higher than
96% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TARO: 34.20 )
Ranked among companies with meaningful ROA (%) only.
TARO' s 10-Year ROA (%) Range
Min: -17  Med: 9.49 Max: 32.05
Current: 34.2
-17
32.05
ROC (Joel Greenblatt) (%) 124.05
TARO's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. TARO: 124.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TARO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -31.27  Med: 25.16 Max: 102.89
Current: 124.05
-31.27
102.89
Revenue Growth (3Y)(%) 21.00
TARO's Revenue Growth (3Y)(%) is ranked higher than
82% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TARO: 21.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TARO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.8  Med: 12.60 Max: 34.7
Current: 21
-6.8
34.7
EBITDA Growth (3Y)(%) 38.90
TARO's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. TARO: 38.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TARO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.3  Med: 38.90 Max: 60.3
Current: 38.9
-24.3
60.3
EPS Growth (3Y)(%) 39.80
TARO's EPS Growth (3Y)(%) is ranked higher than
87% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TARO: 39.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TARO' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 38.40 Max: 102.1
Current: 39.8
0
102.1
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

TARO Guru Trades in Q3 2014

Jim Simons 397,110 sh (+6.98%)
HOTCHKIS & WILEY 275,064 sh (-46.17%)
» More
Q4 2014

TARO Guru Trades in Q4 2014

Jim Simons 403,500 sh (+1.61%)
HOTCHKIS & WILEY 211,499 sh (-23.11%)
» More
Q1 2015

TARO Guru Trades in Q1 2015

Jim Simons 408,606 sh (+1.27%)
HOTCHKIS & WILEY 207,158 sh (-2.05%)
» More
Q2 2015

TARO Guru Trades in Q2 2015

David Dreman 360 sh (New)
Jim Simons 416,600 sh (+1.96%)
HOTCHKIS & WILEY 138,944 sh (-32.93%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.99
TARO's P/E(ttm) is ranked higher than
92% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. TARO: 9.99 )
Ranked among companies with meaningful P/E(ttm) only.
TARO' s 10-Year P/E(ttm) Range
Min: 3.14  Med: 13.54 Max: 477.06
Current: 9.99
3.14
477.06
Forward P/E 11.86
TARO's Forward P/E is ranked higher than
86% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. TARO: 11.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.20
TARO's PE(NRI) is ranked higher than
92% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. TARO: 10.20 )
Ranked among companies with meaningful PE(NRI) only.
TARO' s 10-Year PE(NRI) Range
Min: 3.13  Med: 13.51 Max: 540.67
Current: 10.2
3.13
540.67
P/B 3.73
TARO's P/B is ranked lower than
57% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. TARO: 3.73 )
Ranked among companies with meaningful P/B only.
TARO' s 10-Year P/B Range
Min: 1.07  Med: 2.31 Max: 6.4
Current: 3.73
1.07
6.4
P/S 6.00
TARO's P/S is ranked lower than
72% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. TARO: 6.00 )
Ranked among companies with meaningful P/S only.
TARO' s 10-Year P/S Range
Min: 0.61  Med: 2.12 Max: 9.63
Current: 6
0.61
9.63
PFCF 12.38
TARO's PFCF is ranked higher than
89% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. TARO: 12.38 )
Ranked among companies with meaningful PFCF only.
TARO' s 10-Year PFCF Range
Min: 4.51  Med: 10.02 Max: 28.21
Current: 12.38
4.51
28.21
POCF 11.94
TARO's POCF is ranked higher than
81% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. TARO: 11.94 )
Ranked among companies with meaningful POCF only.
TARO' s 10-Year POCF Range
Min: 4.27  Med: 9.38 Max: 25.85
Current: 11.94
4.27
25.85
EV-to-EBIT 7.09
TARO's EV-to-EBIT is ranked higher than
91% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. TARO: 7.09 )
Ranked among companies with meaningful EV-to-EBIT only.
TARO' s 10-Year EV-to-EBIT Range
Min: -2422.9  Med: 9.50 Max: 59.6
Current: 7.09
-2422.9
59.6
PEG 0.20
TARO's PEG is ranked higher than
98% of the 257 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. TARO: 0.20 )
Ranked among companies with meaningful PEG only.
TARO' s 10-Year PEG Range
Min: 0.21  Med: 0.31 Max: 1.34
Current: 0.2
0.21
1.34
Shiller P/E 20.67
TARO's Shiller P/E is ranked higher than
72% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. TARO: 20.67 )
Ranked among companies with meaningful Shiller P/E only.
TARO' s 10-Year Shiller P/E Range
Min: 6.08  Med: 14.64 Max: 37.29
Current: 20.67
6.08
37.29
Current Ratio 6.31
TARO's Current Ratio is ranked higher than
83% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TARO: 6.31 )
Ranked among companies with meaningful Current Ratio only.
TARO' s 10-Year Current Ratio Range
Min: 0.79  Med: 2.56 Max: 7.27
Current: 6.31
0.79
7.27
Quick Ratio 5.83
TARO's Quick Ratio is ranked higher than
83% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TARO: 5.83 )
Ranked among companies with meaningful Quick Ratio only.
TARO' s 10-Year Quick Ratio Range
Min: 0.55  Med: 1.89 Max: 6.3
Current: 5.83
0.55
6.3
Days Inventory 243.88
TARO's Days Inventory is ranked lower than
90% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. TARO: 243.88 )
Ranked among companies with meaningful Days Inventory only.
TARO' s 10-Year Days Inventory Range
Min: 142.99  Med: 195.36 Max: 261.48
Current: 243.88
142.99
261.48
Days Sales Outstanding 75.77
TARO's Days Sales Outstanding is ranked lower than
54% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. TARO: 75.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
TARO' s 10-Year Days Sales Outstanding Range
Min: 62.91  Med: 97.34 Max: 160.16
Current: 75.77
62.91
160.16

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.81
TARO's Price/Net Cash is ranked higher than
58% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. TARO: 7.81 )
Ranked among companies with meaningful Price/Net Cash only.
TARO' s 10-Year Price/Net Cash Range
Min: 6.83  Med: 14.61 Max: 92.19
Current: 7.81
6.83
92.19
Price/Net Current Asset Value 4.38
TARO's Price/Net Current Asset Value is ranked higher than
70% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. TARO: 4.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TARO' s 10-Year Price/Net Current Asset Value Range
Min: 3.31  Med: 7.18 Max: 730.23
Current: 4.38
3.31
730.23
Price/Tangible Book 3.75
TARO's Price/Tangible Book is ranked higher than
50% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. TARO: 3.75 )
Ranked among companies with meaningful Price/Tangible Book only.
TARO' s 10-Year Price/Tangible Book Range
Min: 0.89  Med: 2.37 Max: 15.98
Current: 3.75
0.89
15.98
Price/Projected FCF 1.22
TARO's Price/Projected FCF is ranked higher than
81% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. TARO: 1.22 )
Ranked among companies with meaningful Price/Projected FCF only.
TARO' s 10-Year Price/Projected FCF Range
Min: 0.93  Med: 1.88 Max: 28.99
Current: 1.22
0.93
28.99
Price/Median PS Value 2.73
TARO's Price/Median PS Value is ranked lower than
88% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. TARO: 2.73 )
Ranked among companies with meaningful Price/Median PS Value only.
TARO' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 1.06 Max: 4.21
Current: 2.73
0.18
4.21
Price/Peter Lynch Fair Value 0.40
TARO's Price/Peter Lynch Fair Value is ranked higher than
94% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. TARO: 0.40 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TARO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.13  Med: 0.95 Max: 33.94
Current: 0.4
0.13
33.94
Price/Graham Number 1.33
TARO's Price/Graham Number is ranked higher than
72% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. TARO: 1.33 )
Ranked among companies with meaningful Price/Graham Number only.
TARO' s 10-Year Price/Graham Number Range
Min: 0.42  Med: 1.23 Max: 10.12
Current: 1.33
0.42
10.12
Earnings Yield (Greenblatt) (%) 14.14
TARO's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TARO: 14.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TARO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.7  Med: 10.10 Max: 21.7
Current: 14.14
1.7
21.7
Forward Rate of Return (Yacktman) (%) 51.36
TARO's Forward Rate of Return (Yacktman) (%) is ranked higher than
96% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.88 vs. TARO: 51.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TARO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -22.3  Med: -3.90 Max: 53
Current: 51.36
-22.3
53

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:TAL.Germany,
Taro Pharmaceutical Industries Ltd was incorporated under the laws of the State of Israel in 1959 under the name Taro-Vit Chemical Industries Ltd. In 1984, it changed its name to Taro Vit Industries Ltd. and in 1994 it changed its name to Taro Pharmaceutical Industries Ltd., which was the name of a subsidiary of Taro Vit Industries Ltd. incorporated under the laws of the State of Israel in 1950. The Company is a multinational, science-based pharmaceutical company. It develops manufactures and markets Rx and OTC pharmaceutical products in the United States, Canada and Israel. Its primary areas of focus include semi-solids formulations such as creams and ointments and other dosage forms such as liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company markets its pharmaceutical products in many countries. The Company competes with the original manufacturers of the brand-name equivalents of its generic products, other generic drug manufacturers including brand-name companies that also manufacture generic drugs or license their products to other generic drug manufacturers and manufacturers of new drugs that may compete with its generic drugs. In Canada, the Company's competition includes Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Valeant Canada, AstraZeneca Canada, Johnson & Johnson Inc., Bayer Inc. and Bristol-Myers Squibb Canada. The Company also competes with other manufacturers of generic products, such as Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated and Pharmascience Inc. In Israel, it competes with Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexcel Pharma Israel, and Rafa Laboratories Ltd., among others. In addition, many multinational companies, including Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc., market their products in Israel. The Company's products and services are subject to pharmaceutical industry regulations in the United States, Canada, Israel and other jurisdictions, and may be subject to future legislative and other regulatory developments concerning its products and the healthcare field generally.
» More Articles for TARO

Headlines

Articles On GuruFocus.com
These Companies Show High Profit and Low Debt Jun 17 2015 
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by Natura Mar 18 2015 
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
taro pharma could double Aug 26 2012 
What do people think of TARO Aug 26 2012 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 
Sun Pharmaceutical Extends Tender Offer for Taro Dec 19 2008 

More From Other Websites
Taro Pharmaceutical Industries Ltd. Earnings Q1, 2015 Aug 26 2015
FDA Approves Taro’s Keveyis™ (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and... Aug 10 2015
Taro Provides Results for Quarter Ended June 2015 Aug 06 2015
Taro to Announce First Quarter Results on August 6, 2015 Jul 30 2015
Hikma Pharmaceuticals Plc: Strong price momentum but will it sustain? Jul 29 2015
Taro Pharmaceutical Industries Ltd Earnings Call scheduled for 8:00 am ET today May 28 2015
Taro Provides Results for Year Ended March 31, 2015 May 26 2015
Taro to Announce Results for Year Ended March 31, 2015 on May 26, 2015 May 19 2015
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by... Mar 18 2015
Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally Mar 05 2015
A. M. Castle & Co (CAS) and Other Bullish Picks of Raging Capital Mar 04 2015
Taro Provides Results for December 31, 2014 Feb 10 2015
Taro to Announce Third Quarter Results on February 10, 2015 Feb 05 2015
Spirit Air, Other Leading Stocks Shaping New Bases Jan 29 2015
Taro Announces Results of Its Annual General Meeting of Shareholders Dec 24 2014
Stock Movers: Why 4 Big Drug Stocks Are Rising Today Nov 18 2014
Taro Provides Results for September 30, 2014 Nov 09 2014
Taro to Announce Second Quarter Results on November 9, 2014 Nov 05 2014
Stock Strength: It's All Relative, And Is Reflected In The RS Line Oct 29 2014
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK